• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Ageing-related markers and risks of cancer and cardiovascular disease: a prospective study in the EPIC-Heidelberg cohort
We examined the associations between five markers of unhealthy ageing; Growth Differentiation Factor-15 (GDF-15), N-terminal pro-brain natriuretic peptide (NT-proBNP), glycated hemoglobin A1c (HbA1C), C-Reactive Protein (CRP) and cystatin-C; with risks of cancer and cardiovascular disease (CVD). We used a case-cohort design embedded in the EPIC-Heidelberg cohort, including a subcohort of 3792 participants along with 4867 incident cases of cancer and CVD. Hazard ratios (HRs) were computed and the strongest associations were used to build weighted multi-marker combinations, and their associations with cancer and CVD risks we...
Source: European Journal of Epidemiology - December 22, 2021 Category: Epidemiology Source Type: research

Cancer Survivorship and Subclinical Myocardial Damage.
Abstract The rate of cardiovascular disease among cancer survivors is higher than in the general population. This difference is due to traditional CVD risk factors and also to the cardiotoxicity of cancer treatment. In a population-based cohort study of 3,512 men and women who were free of CVD at visit 5, Florido et al. evaluated the association of cancer survivorship with subclinical myocardial damage, as assessed by elevated high-sensitivity cardiac Troponin T (hs-cTnT). Cancer survivors had significantly higher odds of elevated hs-cTnT (odds ratio [OR] = 1.26, 95% confidence interval [CI] 1.03, 1.53). Results w...
Source: Am J Epidemiol - July 7, 2019 Category: Epidemiology Authors: Coughlin SS, Kapuku G Tags: Am J Epidemiol Source Type: research

Why is greater medication adherence associated with better outcomes
Background: To evaluate potential explanations for the association of greater adherence to placebo medication with better outcomes. Methods: The three explanations evaluated were that subjects with greater placebo adherence were 1) more likely to adhere to other medications, 2) had better healthcare behaviors, and 3) had lower risk. The data included more than 800 risk factors from the Women's Health Initiative (WHI), a nationwide study that included women who participated in randomized controlled trials of estrogen plus progestin (n=16,608) or estrogen alone (n=10,739). The median follow-up was 8 years. Linear regression ...
Source: Emerging Themes in Epidemiology - February 2, 2013 Category: Epidemiology Authors: Arthur HartzTao He Source Type: research